0001564590-22-019287.txt : 20220510 0001564590-22-019287.hdr.sgml : 20220510 20220510161820 ACCESSION NUMBER: 0001564590-22-019287 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220510 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220510 DATE AS OF CHANGE: 20220510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 22909915 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 8-K 1 virx-8k_20220510.htm 8-K virx-8k_20220510.htm
false 0001061027 0001061027 2022-05-10 2022-05-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2022

 

 

VIRACTA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-51531

94-3295878

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2533 S. Coast Hwy. 101, Suite 210

 

Cardiff, California

 

92007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 400-8470

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VIRX

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On May 10, 2022, Viracta Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

All of the information furnished in this Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

 

 

Number

 

Description

 

 

 

99.1

 

Press Release, dated May 10, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Viracta Therapeutics, Inc.

 

 

 

 

Date:

May 10, 2022

By:

/s/ Daniel Chevallard

 

 

 

Daniel Chevallard
Chief Operating Officer and Chief Financial Officer

 

 EX-99.1 2 d333155dex991.htm EX-99.1
Exhibit 99.1

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage 2 anticipated in the second half of 2022

Preliminary safety and efficacy data for the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors anticipated in the second half of 2022

Cash balance of $92.2 million as of March 31, 2022; projected cash runway into mid-2024

SAN DIEGO, May 10, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today reported financial results for the first quarter of 2022 and provided an update on recent corporate progress.

"We have made encouraging progress in both clinical programs with our all-oral drug product candidate, Nana-val, which are advancing towards potential key catalysts in the second half of the year," said Ivor Royston, M.D., President and Chief Executive Officer of Viracta. "Since the first patient was dosed in January, our Phase 1b/2 trial of Nana-val in patients with advanced EBV-positive solid tumors has proceeded nicely and we anticipate reporting preliminary safety and efficacy data later this year. In addition, we are pleased to have expanded the clinical reach of NAVAL-1 beyond North America into Europe as well as Asia, and anticipate having an update on cohorts advancing into Stage 2 of the trial later this year."

First Quarter 2022 and Recent Highlights

Clinical

  • Continued global expansion and enrollment into NAVAL-1, the pivotal trial of Nana-val (nanatinostat and valganciclovir) for the treatment of patients with relapsed/refractory EBV+ lymphoma. NAVAL-1 employs a Simon two-stage design where patients are initially enrolled into six cohorts based on lymphoma subtype in Stage 1. If a pre-specified activity threshold is reached, additional patients will be enrolled in Stage 2. Lymphoma subtypes demonstrating promising activity in Stage 2 may be further expanded. If successful, the Company believes NAVAL-1 could potentially support multiple new drug application filings across various EBV+ lymphoma subtypes. Clinical sites are open across the globe, including in the U.S., Canada, Europe, and Asia. The Company anticipates providing an update on the initial cohort(s) that may advance into Stage 2 of the trial in the second half of the year.
  • Dosed first patient in the Phase 1b/2 trial of Nana-val in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and other EBV+ solid tumors. Enrollment continues in the Phase 1b dose escalation part of the study, which is designed to evaluate safety and determine the recommended Phase 2 dose (RP2D) of Nana-val in patients with EBV+ R/M NPC. In Phase 2, up to 60 patients with EBV+ R/M NPC will be randomized to receive Nana-val at the RP2D with or without pembrolizumab to evaluate safety and preliminary efficacy. Additionally, patients with other EBV+ solid tumors will be enrolled to receive Nana-val at the RP2D in a Phase 1b dose expansion cohort. Viracta anticipates reporting preliminary Phase 1b safety and efficacy data from the trial in the second half of 2022.

Corporate

  • Hosted key opinion leader webinar on Nana-val for the treatment of advanced EBV+ solid tumors. The webinar featured presentations from key opinion leader Ezra Cohen, MD, FRCPSC, FASCO (University of California, San Diego) and members of the Viracta management team. Topics discussed included the current treatment landscape and unmet medical need in NPC, the design of the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors, and preclinical data supporting the trial. A replay of the webinar is available here.

Anticipated 2022 Milestones

  • Provide preliminary Phase 1b safety and efficacy data from the Phase 1b/2 trial in advanced EBV+ solid tumors: 2H 2022
  • Update on NAVAL-1 cohort(s) that may progress from Stage 1 to Stage 2: 2H 2022

First Quarter 2022 Financial Results

  • Cash Position – Cash and cash equivalents totaled approximately $92.2 million as of March 31, 2022, which Viracta expects will be sufficient to fund its operations into mid-2024, excluding any borrowing under its previously announced $50.0 million credit facility from Silicon Valley Bank and Oxford Finance.
  • Research and development expenses – Research and development expenses were approximately $6.1 million for the three months ended March 31, 2022, compared to $4.0 million for the same period in 2021. The increase in research and development expenses for the three months ended March 31, 2022, was primarily due to increases in costs incurred to support the initiation of the NAVAL-1 and solid tumor trials as well as an increase in headcount and non-cash share-based compensation.
  • Acquired in-process research and development – For the three months ended March 31, 2021, the acquired in-process research and development included non-cash and non-recurring cost of $84.5 million associated with the estimated fair value of the in-process research and development projects acquired in the Sunesis asset acquisition with no alternative future use, which was charged to expense on the Sunesis merger date.
  • General and administrative expenses – General and administrative expenses were approximately $4.3 million for the three months ended March 31, 2022, compared to $3.8 million for the same period in 2021. The increase was largely due to incremental costs associated with being a publicly traded company including directors and officers' insurance costs, and non-cash share-based compensation.
  • Gain on Royalty Purchase Agreement – For the three months ended March 31, 2021, the gain was associated with upfront proceeds of $13.5 million recorded in connection with the multi-license milestone and royalty monetization transaction with XOMA (US) LLC.
  • Adjusted loss from operations – There was not a comparative adjustment to loss from operations for the quarter ended March 31, 2022. Adjusted income from operations for the quarter ended March 31, 2021, excluding the non-recurring and non-cash operating expenses associated with the write-off of in-process research and development acquired in the merger (a non-GAAP measure) was $5.6 million, compared to an unadjusted loss from operations of $78.8 million.
  • Net loss – Net loss was approximately $10.5 million, or $0.28 per share (basic and diluted) for the quarter ended March 31, 2022, compared to a net loss of $79.2 million or $5.22 per share for the same period in 2021.

About Nana-val (Nanatinostat and Valganciclovir)

Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-val, in various subtypes of EBV-associated malignancies. Ongoing trials include a pivotal, global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1) as well as a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

About EBV-Associated Cancers

Approximately 90% of the world's adult population is infected with Epstein-Barr virus (EBV). Infections are commonly asymptomatic or associated with mononucleosis. Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patient's life. Cells containing latent virus are increasingly susceptible to malignant transformation. Patients who are immunocompromised are at an increased risk of developing EBV+ lymphomas. EBV is estimated to be associated with approximately 2% of the global cancer burden and is also associated with a variety of solid tumors, including nasopharyngeal carcinoma and gastric cancer.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a multinational Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Forward-Looking Statements

This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for Viracta's ongoing trials and updates regarding the same; the significance of the Nana-val trial results, NAVAL-1 as a potential registration-enabling trial, the utility Viracta's therapeutic approach, the strength of Viracta's clinical dataset, the ability of Viracta to obtain one or more accelerated approvals, the timeline for further clinical program updates in the second half of 2022; Viracta's plans to provide updates on NAVAL-1 in the second half of 2022; expectations regarding the Company's pipeline and potential products; Viracta's cash projections and the sufficiency its cash and cash equivalents to fund operations into 2024; the future availability of capital under Viracta's credit facility; the expected 2022 milestones and key upcoming events and their significance; and other statements that are not historical facts. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; Viracta's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta's competitors and its industry; the impact of government laws and regulations; Viracta's ability to protect its intellectual property position; and Viracta's estimates regarding future expenses, capital requirements and need for additional financing in the future.

These risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

Financials Attached

Viracta Therapeutics, Inc.

Selected Balance Sheet Highlights

(in thousands)






March 31,

December 31,

2022

2021

(Unaudited)


Cash and cash equivalents

$

92,199

$

103,554

Total assets

$

98,387

$

108,552

Total liabilities

$

12,782

$

14,181

Stockholders' equity

$

85,605

$

94,371





Viracta Therapeutics, Inc.

Condensed Consolidated Statement of Operations and Comprehensive Loss

(in thousands except share and per share data)

(Unaudited)



Three Months Ended March 31,

2022

2021

Operating expenses:




Research and development

$

6,096

$

4,024

Acquired in-process research and development

—

84,478

General and administrative

4,336

3,840

Total operating expenses

10,432

92,342

Gain on Royalty Purchase Agreement

—

13,500

Loss from operations

(10,432)

(78,842)

Total other expense

(114)

(389)

Net loss and comprehensive loss

$

(10,546)

$

(79,231)

Net loss per share, basic and diluted

$

(0.28)

$

(5.22)

Weighted-average common shares
outstanding, basic and diluted

37,535,874

15,166,737





Viracta Therapeutics, Inc.

Reconciliation of GAAP Loss from Operations to Adjusted (Loss) Income from Operations

(in thousands)

(Unaudited)

Three Months Ended March 31,

2022

2021




Loss from operations

$

(10,432)

$

(78,842)

Less: Acquired in-process research and development

-

84,478

Adjusted (loss) income from operations

$

(10,432)

$

5,636



 GRAPHIC 3 d333155dlogo.jpg GRAPHIC begin 644 d333155dlogo.jpg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end EX-101.SCH 4 virx-20220510.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 virx-20220510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 virx-20220510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 10, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 10, 2022
Entity Registrant Name VIRACTA THERAPEUTICS, INC.
Entity Central Index Key 0001061027
Entity Emerging Growth Company false
Entity File Number 000-51531
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3295878
Entity Address, Address Line One 2533 S. Coast Hwy. 101
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Cardiff
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92007
City Area Code (858)
Local Phone Number 400-8470
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol VIRX
Security Exchange Name NASDAQ
XML 8 virx-8k_20220510_htm.xml IDEA: XBRL DOCUMENT 0001061027 2022-05-10 2022-05-10 false 0001061027 8-K 2022-05-10 VIRACTA THERAPEUTICS, INC. DE 000-51531 94-3295878 2533 S. Coast Hwy. 101 Suite 210 Cardiff CA 92007 (858) 400-8470 false false false false Common Stock, par value $0.0001 per share VIRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports virx-8k_20220510.htm d333155dex991.htm virx-20220510.xsd virx-20220510_lab.xml virx-20220510_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "virx-8k_20220510.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "virx-8k_20220510.htm" ] }, "labelLink": { "local": [ "virx-20220510_lab.xml" ] }, "presentationLink": { "local": [ "virx-20220510_pre.xml" ] }, "schema": { "local": [ "virx-20220510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "virx", "nsuri": "http://viracta.com/20220510", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "virx-8k_20220510.htm", "contextRef": "C_0001061027_20220510_20220510", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "virx-8k_20220510.htm", "contextRef": "C_0001061027_20220510_20220510", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viracta.com/20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-019287-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-019287-xbrl.zip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